Soluble urokinase-type plasminogen activator receptor as a measure of treatment response in acute exacerbation of COPD
Jornal Brasileiro de Pneumologia · 2018-02 · 44 (1) · 36-41
DOI: 10.1590/s1806-37562017000000151 ↗Kurz gefasst
Fachartikel in der Zeitschrift Jornal Brasileiro de Pneumologia, 2018-02. Verfasst von Gehan Hassan AboEl-Magd und 1 weiteren Autor:innen. Beteiligte Einrichtung: . Chest Department, Faculty of Medicine, Tanta University, Tanta, Gharbia, Egypt. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: COPD
Abstract (Originalsprache)
Objective
To evaluate the value of soluble urokinase-type plasminogen activator receptor (suPAR) in the diagnosis of acute exacerbation of COPD (AECOPD) and in monitoring treatment response, analyzing the relationship between suPAR and fibrinogen in AECOPD. AECOPD leads to increased airway inflammation, contributing to an exaggerated release of inflammatory mediators.
Methods
We recruited 45 patients with AECOPD and 20 healthy control subjects. Medical histories were taken, and all subjects underwent clinical examination, chest X-ray, pulmonary function tests, and blood gas analysis. On day 1 (treatment initiation for the AECOPD patients) and day 14 (end of treatment), blood samples were collected for the determination of serum suPAR and plasma fibrinogen.
Results
Serum levels of suPAR were significantly higher in the AECOPD group than in the control group. In the AECOPD patients, there was a significant post-treatment decrease in the mean serum suPAR level. The sensitivity, specificity, and accuracy of suPAR were 95.6%, 80.0%, and 93.0%, respectively. The Global Initiative for Chronic Obstructive Lung Disease stage (i.e., COPD severity) correlated positively and significantly with serum levels of suPAR and plasma levels of fibrinogen.
Conclusions
Monitoring the serum suPAR level can be helpful in the evaluation of the COPD treatment response and might be a valuable biomarker for determining the prognosis of AECOPD. Because serum suPAR correlated with plasma fibrinogen, both markers could be predictive of AECOPD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- . Chest Department, Faculty of Medicine, Tanta University, Tanta, Gharbia, Egypt.
- . Clinical Pathology Department, Faculty of Medicine, Tanta University, Tanta, Gharbia, Egypt.
Zitieren
APA
AboEl-Magd, G. H., & Mabrouk, M. M. (2018). Soluble urokinase-type plasminogen activator receptor as a measure of treatment response in acute exacerbation of COPD. Jornal Brasileiro de Pneumologia, 44(1), 36-41. https://doi.org/10.1590/s1806-37562017000000151
Vancouver
AboEl-Magd GH, Mabrouk MM. Soluble urokinase-type plasminogen activator receptor as a measure of treatment response in acute exacerbation of COPD. Jornal Brasileiro de Pneumologia. 2018;44(1):36-41. doi:10.1590/s1806-37562017000000151
BibTeX
@article{AboElMagd2018,
author = {AboEl-Magd, Gehan Hassan and Mabrouk, Maaly Mohamed},
title = {Soluble urokinase-type plasminogen activator receptor as a measure of treatment response in acute exacerbation of COPD},
journal = {Jornal Brasileiro de Pneumologia},
year = {2018},
volume = {44},
number = {1},
pages = {36--41},
doi = {10.1590/s1806-37562017000000151}
}
EUVIMED